93 results on '"Dreesen, Erwin"'
Search Results
2. Personalized Antifungal Therapy Through Model-Informed Precision Dosing of Posaconazole
3. Agreement Between a Colorimetric Assay and Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry for Quantifying Paracetamol Plasma Concentrations
4. Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study
5. TRPA1 Antagonist LY3526318 Inhibits the Cinnamaldehyde‐Evoked Dermal Blood Flow Increase: Translational Proof of Pharmacology
6. Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates
7. Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review
8. A personalised taper-to-target strategy with adalimumab in Crohn's disease
9. Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review
10. A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases
11. Liposomal amphotericin B exposure in critically ill patients: a prospective pharmacokinetic study
12. Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in Adults
13. Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia
14. Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases
15. Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders
16. Editorial: Therapeutic Drug Monitoring (TDM): A Useful Tool for Pediatric Pharmacology Applied to Routine Clinical Practice
17. 234: INFLIXIMAB CLEARANCE PRE-THERAPY AND DURING INDUCTION PREDICTS LONG TERM DISEASE CONTROL IN INFLAMMATORY BOWEL DISEASE
18. Mo1521: PROACTIVE DOSE INTENSIFICATION BY PRECISION-GUIDED DOSING YIELDS ENHANCED DISEASE CONTROL IN INFLAMMATORY BOWEL DISEASE
19. Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA‐FLU study
20. Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis
21. The TARGET trial as a plea for model-informed precision dosing of piperacillin/tazobactam in patients with sepsis
22. Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies
23. Recent advancements in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases
24. Prospective assessment of breakthrough infections and neurotoxicity and their association with cefepime trough concentrations in patients with febrile neutropenia
25. Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function
26. Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy
27. Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study
28. Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
29. Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model
30. Population pharmacokinetics of cefazolin in maternal and umbilical cord plasma, and simulated exposure in term neonates
31. New Tools for Therapeutic Drug Monitoring: Making Big Things out of Small Pieces
32. Bosentan Alters Endo- and Exogenous Bile Salt Disposition in Sandwich-Cultured Human Hepatocytes
33. A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication
34. Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis
35. Population pharmacokinetic‐pharmacodynamic model‐based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease
36. Corrigendum to “itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens”
37. Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study
38. Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis
39. Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics
40. Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study
41. Su433 MODEL-BASED IDENTIFICATION OF AN OPTIMIZED USTEKINUMAB DOSAGE REGIMEN FOR PATIENTS WITH CROHN'S DISEASE
42. Su439 THE VALUE OF COMBINED SERUM INFLIXIMAB AND ENDOSCOPIC HEALING INDEX MONITORING FOR GUIDING INFLIXIMAB DOSING IN PATIENTS WITH CROHN'S DISEASE
43. Su438 THE EFFECT OF AGING ON INFLIXIMAB EXPOSURE AND RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
44. Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease
45. Su434 A POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODEL OF VEDOLIZUMAB TO TARGET ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN'S DISEASE: POST HOC ANALYSIS OF THE LOVE-CD STUDY
46. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial
47. The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases
48. Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation
49. Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies
50. Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.